Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

BACKGROUND: Axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, enhanced the efficacy of chemotherapy in human xenograft tumour models. This phase I study investigated the safety, tolerability, pharmacokinetics and antitumour activity of axit...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, L P, Kozloff, M F, Herbst, R S, Samuel, T A, Kim, S, Rosbrook, B, Tortorici, M, Chen, Y, Tarazi, J, Olszanski, A J, Rado, T, Starr, A, Cohen, R B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494424/
https://www.ncbi.nlm.nih.gov/pubmed/22996612
http://dx.doi.org/10.1038/bjc.2012.407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494424/
https://www.ncbi.nlm.nih.gov/pubmed/22996612
http://dx.doi.org/10.1038/bjc.2012.407

Ejemplares similares